Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2020-11-04 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关于5%以上股东减持计划完成的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the completion of a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the shareholder's name, the number of shares reduced, the method of reduction (block trade), the period of reduction, and the impact on shareholding percentages. It also confirms compliance with relevant securities laws and regulations. This type of document is a notification about changes in major shareholdings, specifically a reduction in shareholding by a significant shareholder. It does not contain financial statements, management discussion, or other report content. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or announcement of a report publication.
2020-11-04 Chinese
关于公司获得政府补助的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about receiving government subsidies, detailing amounts, dates, and reasons for the subsidies. It includes no financial statements, no management discussion of financial results, no earnings highlights, no meeting materials, no voting results, no legal proceedings, no capital changes, and no executive changes. The document is relatively short (3602 characters) and is a formal disclosure of government grants received, which is a regulatory announcement to inform investors and the market. It does not constitute a full financial report or audit report but is a regulatory filing informing about government subsidies. Therefore, the best fitting category is Regulatory Filings (RNS).
2020-11-02 Chinese
关于召开2020年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2020 second extraordinary general meeting of shareholders for Xiamen Aide Bio-pharmaceutical Technology Co., Ltd. It includes information about the meeting date, location, agenda items, voting procedures, registration methods, and proxy forms. The content focuses on the announcement and procedural details for the shareholders' meeting rather than the results of the vote or the meeting itself. There is no indication that this document contains the voting results or a summary of the meeting outcomes. Therefore, it is best classified as a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2020-10-20 Chinese
公司章程
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 厦门艾德生物医药科技股份有限公司 (Amoy Diagnostics Co., LTD). It contains detailed chapters on company organization, shareholder rights, board structure, share issuance, share transfer, shareholder meetings, and other governance-related provisions. It is a comprehensive legal document that governs the internal rules and governance practices of the company. There is no indication that this is a report of financial performance, audit, or an announcement. It is not a proxy statement or voting results announcement. The document is clearly the company's Articles of Association, which falls under Governance Information (CGR) as it details the company's internal rules, board structure, and governance practices.
2020-10-20 Chinese
关于调整2019年限制性股票激励计划相关事项的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding adjustments to its 2019 restricted stock incentive plan, including details about board and supervisory meetings, approvals, and legal opinions. It discusses changes in stock repurchase prices and quantities related to the incentive plan. The document is not a full financial report, earnings release, or management discussion, but rather a formal announcement about changes to a stock incentive plan and related corporate governance matters. It does not contain financial statements or detailed financial analysis. The document is also relatively short (4380 characters) and reads as a formal announcement rather than a full report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-10-20 Chinese
独立董事关于相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on specific company matters including adjustments to a 2019 restricted stock incentive plan, repurchase and cancellation of restricted shares, and the use of idle funds for cash management. It references compliance with regulatory guidelines and company rules but does not contain financial statements or detailed financial results. The document is a formal opinion related to governance and management decisions rather than a full report or announcement of voting results. It is not a full Annual Report, Audit Report, or Earnings Release. It is also not a simple announcement or certification. The content aligns best with Board/Management Information (MANG) as it involves board-level decisions and independent directors' opinions on company management matters.
2020-10-20 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.